INTRODUCTION
============

Ovarian cancer is one of the five leading cause of cancer death among all malignancies worldwide \[[@B1]\]. Further, it is estimated to be the 8th most common cause of death and its incidence has increased approximately 50% over the recent 10 years in Korea \[[@B2][@B3]\]. Treatment of ovarian cancer includes primary debulking surgery followed by chemotherapy. Incorporation of bevacizumab has been shown to improve survival outcome \[[@B4]\], but a majority of the patients (75%) still experience recurrence and succumb (70%) within five years \[[@B5]\]. Further, the use of bevacizumab is limited by its high cost and numerous adverse effects such as genitourinary fistula, gastrointestinal tract perforation, and hypertension in ovarian cancer patients \[[@B4]\]. Therefore, better therapeutic strategies are needed. The concept of drug repurposing is an alternative method to find promising therapeutic agents by uncovering anti-cancer effects of previously known drugs, reducing the cost, and time involved in finding investigational new drugs (INDs) \[[@B6]\].

Previous pre-clinical studies have shown that beta adrenergic receptors are commonly expressed on the surface of ovarian cancer cells \[[@B7]\]. Activation of these receptors by catecholamines produced due to chronic stress was found to be associated with carcinogenesis and tumor progression via evasion from apoptosis and acquisition of resistance to chemotherapy \[[@B8][@B9][@B10]\]. Catecholamines activate and enhance the expression of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) via the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway. These events increase invasiveness and metastatic potential of tumors leading to a higher tumor stage and worse survival outcomes in ovarian cancer \[[@B8][@B9][@B11]\]. Surprisingly, these pathways were found to be downregulated and even reversed when beta blockers (BBs) were administered to mice in previous preclinical studies \[[@B12][@B13][@B14]\].

Based on such promising evidence, a number of clinical studies sought to evaluate BBs for ovarian cancer treatment, but the results obtained were conflicting \[[@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21]\]. Ovarian cancer possesses a variable genetic background with characteristics differing between region and country. It is likely that each nation will need their own surveys and investigations to understand how BBs affect ovarian cancer prognosis in the context of multi-factorial social change. BBs are a treatment of choice for managing hypertension worldwide including Korea. In addition, they are widely used to control cardiac arrhythmia, congestive heart failure, anxiety, and for secondary prevention of myocardial infarction \[[@B10]\]. It is because they are economically and ethically sound for both patients and researchers. Above all, their safety has been widely accepted over a long history of use. The proportion of the elderly is on the rise in Korea and use of BBs is likely to increase due to higher incidence of hypertension and related heart diseases. If BBs have an anticancer effect, they can be potential therapeutic agents to relieve the financial burden involved in cancer therapy. Therefore, we performed a nationwide population-based cohort study to investigate the impact of BBs on survival outcomes in ovarian cancer.

MATERIALS AND METHODS
=====================

Data
----

Data collected in the South Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC) database from 2002 to 2013 (released by NHIS in 2014) was used to perform the study. All individuals are enrolled in the NHIS, and NHIS-NSC represents the entire South Korean population (n=46,605,433) in terms of every demographic background with no significant differences \[[@B22]\]. The NHIS made available an encrypted 2.2% sample of the database (n=1,025,340) (national representative cohort) for researchers in 2002. This was constructed via random stratified sampling per 5-year age groups, gender, income status, prescriptions, diagnosis, mortality, and health insurance status. The data is renewed every year by adding random samples of newborns and deletion of individuals undergoing death or emigration.

Study cohort
------------

The 6th edition of the Korean Classification of Disease (KCD-6), which is a Korean version of the International Classification of Disease, 10th Revision (ICD-10) has been coded to categorize all diagnoses. We only included patients who were diagnosed with ovarian cancer (C56) and had a record of hospital admission due to ovarian cancer. Only patients who were older than 20 years of age at the time of diagnosis were included. Further, only patients who had a medical record of ≥1 year & follow up of ≥3 years before & after the diagnosis were included for better data accuracy and analysis ([Fig. 1](#F1){ref-type="fig"}).

![Flow diagram of selection of the study patients.\
BB, beta blocker; ICD-10, International Classification of Disease, 10th Revision; NSBB, non-selective beta blocker; SBB, selective beta blocker.](jgo-29-e82-g001){#F1}

Definition of BB use
--------------------

Both brand and generic names of drugs (based on the drug formulary code of the Korean Health Insurance Review and Assessment service), the prescription date, the number of days of supply, and administration route were found in the prescription data. This was coded based on the Anatomical Therapeutic Chemical (ATC) classification system. Selective beta blockers (SBBs) are drugs that block one of the beta1/2 adrenoreceptors. Non-selective beta blockers (NSBBs) are drugs that block all subtypes of beta adrenoreceptors. BB users were defined as individuals with at least one prescription within 90 days of diagnosis. Patients were classified as non-users when there was no prescription within 90 days of diagnosis, because it is customary in Korea to prescribe for 30-90 days period for long-term users.

Mortality
---------

In total, follow-up data for the cohort over a 12-year period until 2013 were available in the database. Follow-up was performed from the date of diagnosis until the last visit, death, or emigration, whichever was first. Information on all-cause and disease specific mortality for all individuals in the cohort was analyzed.

Confounders
-----------

Potential confounders such as co-morbidities and medications were identified by sorting based on the ICD-10 and ATC codes. Prior use of diuretics, aspirin, statins, and year of diagnosis were assessed. Information on history and diagnosis of myocardial infarction, congestive heart failure, peripheral vessel disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, gastric ulcer, liver disease, diabetes mellitus with/without associated complication, hemiparesis, kidney disease, hematological malignancies, acquired immune-deficiency syndrome (AIDs), and other co-existing malignancies was obtained. The Charlson Comorbidity Index (CCI) was used to categorize and measure the burden of co-morbid diseases \[[@B23]\]. Multivariate Cox proportional hazard model was generated to identify an independent prognostic factor.

Statistical analysis
--------------------

The proportion and frequency of deaths, covariates, and amount of accumulated person-time were calculated. Survival curves were constructed using Kaplan-Meier estimates and compared with results of the log-rank test. Cox proportional hazard regression was adopted to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Risk factor modeling was used to build a multivariate model including prior use of other medication, CCI, age group, and year of diagnosis. The p\<0.05 was defined as the threshold for statistical significance. SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA) was used for statistical analysis.

Ethical approval
----------------

This study was approved from the Institutional Review Board review (No. 2016-I084) in Hallym University Sacred Heart Hospital.

RESULTS
=======

We analyzed the mortality HRs in ovarian cancer patients based on BB medication use in various cohorts.

Impact of age
-------------

Among the 866 ovarian cancer patients, 206 (23.8%) were BB users and 660 (76.2%) were non-users. Among the 206 BB users, 151 (73.3%) were NSBB users and 105 (51.0%) were SBB users. Fifty (24.3%) patients were taking both NSBB and SBB ([Fig. 1](#F1){ref-type="fig"}).

The median follow-up period was 5.98 and 6.71 years for non-users and users, respectively. In total, there was no survival difference between the 2 groups (HR=1.046; 95% CI=0.799--1.368; p=0.745). However, when patients were sub-grouped based on their age at diagnosis, BB was associated with better survival outcome in patients of age ≥60 (adjusted HR=0.579; 95% CI=0.408--0.823; p=0.002). Both NSBB (adjusted HR=0.565; 95% CI=0.377--0.848; p=0.006) and SBB (adjusted HR=0.523; 95% CI=0.332--0.827; p=0.005) were associated with better survival outcomes in patients of age ≥60 ([Table 1](#T1){ref-type="table"} and [Fig. 2A](#F2){ref-type="fig"}).

###### Mortality HRs in ovarian cancer patients using BBs, based on age at diagnosis

![](jgo-29-e82-i001)

  Variables              No.         Number of deaths (%)   Median years of follow-up   Crude HR   95% CI          p value        Adjusted HR^\*^   95% CI          p value                       
  ---------------------- ----------- ---------------------- --------------------------- ---------- --------------- -------------- ----------------- --------------- -------------- -------------- -------
  Overall                                                                                                                                                                                         
                         No BB use   660                    210                         5.98       1 (reference)                                    1 (reference)                                 
                         BB use      206                    71                          6.71       1.046           0.799--1.368   0.745                                                           
                                     NSBB                   151                         48         6.36            0.951          0.695--1.301      0.754                                         
                                     SBB                    105                         36         7.39            1.005          0.705--1.431      0.980                                         
  20--39 years (n=216)                                                                                                                                                                            
                         No BB use   198                    19                          6.48       1 (reference)                                    1 (reference)                                 
                         BB use      18                     3                           6.15       1.679           0.496--5.676   0.405             0.769           0.222--2.669   0.680          
                                     NSBB                   17                          3          6.66            1.755          0.519--5.934      0.366           0.814          0.234--2.830   0.747
                                     SBB                    1                           0          3.36            \-                               \-                                            
  40--59 years (n=350)                                                                                                                                                                            
                         No BB use   280                    83                          5.98       1 (reference)                                    1 (reference)                                 
                         BB use      70                     16                          7.28       0.696           0.407--1.189   0.185             1.020           0.559--1.860   0.949          
                                     NSBB                   51                          10         7.17            0.584          0.303--1.126      0.108           0.829          0.399--1.724   0.615
                                     SBB                    39                          9          7.92            0.687          0.345--1.367      0.285           1.024          0.478--2.196   0.951
  ≥60 years (n=300)                                                                                                                                                                               
                         No BB use   182                    108                         5.39       1 (reference)                                    1 (reference)                                 
                         BB use      118                    52                          6.13       0.604           0.434--0.842   0.003             0.579           0.408--0.823   0.002          
                                     NSBB                   83                          35         5.75            0.580          0.396--0.849      0.005           0.565          0.377--0.848   0.006
                                     SBB                    65                          27         7.12            0.534          0.350--0.815      0.004           0.523          0.332--0.827   0.005

BB, beta blocker; CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio; NSBB, non-selective beta blocker; SBB, selective beta blocker.

^\*^Adjusted for comorbidity level, prior use of diuretics (yes/no), year of diagnosis, aspirin (yes/no), and statins (yes/no). Comorbidity was computed using the CCI score categorized into low (0), medium (1--2), or high (3+).

![(A) OS and DSS in patients with ovarian cancer based on BB use (NSBB or SBB) and no BB use. (B) OS and DSS in patients (age ≥60) with ovarian cancer based on BB use (NSBB or SBB) and no BB use.\
BB, beta blocker; DSS, disease-specific survival; NSBB, non-selective beta blocker; OS, overall survival; SBB, selective beta blocker.](jgo-29-e82-g002){#F2}

Impact of duration of medication
--------------------------------

Longer duration of BB medication (≥1 year) was associated with better survival outcome in patients with ovarian cancer regardless of BB type (adjusted HR=0.306; 95% CI=0.187--0.501; p\<0.001). When patients were analyzed based on days of medication use, NSBB was associated with better survival outcome when it was used for ≥180 days (adjusted HR=0.387; 95% CI=0.179--0.837; p=0.016), while such a finding was observed in the SBB group with a longer duration of medication of ≥720 days (adjusted HR=0.275; 95% CI=0.111--0.684; p=0.005, [Table 2](#T2){ref-type="table"} and [Fig. 3](#F3){ref-type="fig"}).

###### Mortality HRs in ovarian cancer patients using BBs, based on duration of use

![](jgo-29-e82-i002)

  Variables            No.                                     Number of deaths (%)   Median years of follow-up   Crude HR   95% CI          p value        Adjusted HR^\*^   95% CI          p value        
  -------------------- --------------------------------------- ---------------------- --------------------------- ---------- --------------- -------------- ----------------- --------------- -------------- -------
  Overall                                                                                                                                                                                                    
                       Nonusers                                660                    210                         5.98       1 (reference)                                    1 (reference)                  
                       Current users with \<1 years BB use     119                    52                          6.08       1.475           1.089--1.998   0.012             1.045           0.758--1.439   0.789
                       Current users with ≥1 years BB use      87                     19                          7.12       0.581           0.363--0.930   0.024             0.306           0.187--0.501   0.000
                       Current users with \<1 years NSBB use   99                     38                          6.28       1.222           0.865--1.726   0.256             0.845           0.583--1.225   0.374
                       Current users with ≥1 years NSBB use    52                     10                          6.57       0.516           0.274--0.974   0.041             0.292           0.151--0.563   0.000
                       Current users with \<1 years SBB use    69                     27                          7.15       1.213           0.812--1.810   0.346             0.754           0.492--1.154   0.193
                       Current users with ≥1 years SBB use     36                     9                           7.49       0.663           0.340--1.292   0.227             0.340           0.169--0.683   0.002
  Current BB users                                                                                                                                                                                           
                       \<180 days                              96                     44                          6.32       1.580           1.141--2.186   0.006             1.111           0.788--1.566   0.547
                       ≥180 & \<720 days                       47                     15                          5.27       0.977           0.579--1.650   0.932             0.528           0.308--0.904   0.020
                       ≥720 days                               63                     12                          8.34       0.485           0.271--0.868   0.015             0.279           0.153--0.511   0.000
  Current NSBB users                                                                                                                                                                                         
                       \<180 days                              90                     36                          6.38       1.295           0.909--1.844   0.152             0.913           0.624--1.337   0.641
                       ≥180 & \<720 days                       28                     7                           5.29       0.722           0.340--1.534   0.398             0.387           0.179--0.837   0.016
                       ≥720 days                               33                     5                           7.43       0.386           0.159--0.936   0.035             0.235           0.095--0.579   0.002
  Current SBB users                                                                                                                                                                                          
                       \<180 days                              52                     21                          6.08       1.273           0.813--1.993   0.292             0.705           0.438--1.133   0.149
                       ≥180 & \<720 days                       29                     10                          7.39       1.025           0.543--1.932   0.940             0.718           0.373--1.384   0.322
                       ≥720 days                               24                     5                           8.82       0.522           0.215--1.267   0.150             0.275           0.111--0.684   0.005

BB, beta blocker; CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio; NSBB, non-selective beta blocker; SBB, selective beta blocker.

^\*^Adjusted for age (20--39, 40--59, 60--79, ≥80 years), comorbidity level, prior use of diuretics (yes/no), year of diagnosis, aspirin (yes/no), and statins (yes/no). Comorbidity was computed using the CCI score categorized into low (0), medium (1--2), or high (3+).

![OS and DSS of patients with ovarian cancer based on duration of use of (A) BB, (B) NSBB, or (C) SBB.\
BB, beta blocker; DSS, disease-specific survival; NSBB, non-selective beta blocker; OS, overall survival; SBB, selective beta blocker.](jgo-29-e82-g003){#F3}

Impact of CCI
-------------

There was no survival difference between the CCI 0 (adjusted HR=1.080; 95% CI=0.119--9.812; p=0.946) and 1--2 (adjusted HR=0.561; 95% CI=0.217--1.451; p=0.233) groups of ovarian cancer patients using BB medication. However, BB medication use was associated with better survival outcomes in ovarian cancer patients with CCI ≥3 (adjusted HR=0.690; 95% CI=0.502--0.949; p=0.023). Both NSBB (adjusted HR=0.633; 95% CI=0.438--0.913; p=0.014) and SBB (adjusted HR=0.642; 95% CI=0.424--0.971; p=0.036) were associated with better survival outcomes in patients with CCI ≥3 ([Table 3](#T3){ref-type="table"} and [Fig. 4A](#F4){ref-type="fig"}).

###### Mortality HRs in ovarian cancer patients using BBs, based on the CCI, presence of hypertension, and cardiovascular disease
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  Variables                           No.         Number of deaths (%)   Median years of follow-up   Crude HR   95% CI          p value        Adjusted HR^\*^   95% CI          p value                        
  ----------------------------------- ----------- ---------------------- --------------------------- ---------- --------------- -------------- ----------------- --------------- -------------- --------------- -------
  CCI 0 (n=131)                                                                                                                                                                                                 
                                      No BB use   111                    5                           6.06       1 (reference)                                    1 (reference)                                  
                                      BB use      20                     1                           8.63       0.814           0.093--7.110   0.853             1.080           0.119--9.812   0.946           
                                                  NSBB                   12                          1          7.18            1.537          0.179--13.221     0.695           2.659          0.250--28.321   0.418
                                                  SBB                    9                           0          9.80            \-                               \-                                             
  CCI 1--2 (n=219)                                                                                                                                                                                              
                                      No BB use   186                    34                          5.97       1 (reference)                                    1 (reference)                                  
                                      BB use      33                     6                           7.45       0.946           0.397--2.257   0.901             0.561           0.217--1.451   0.233           
                                                  NSBB                   24                          4          7.28            0.856          0.303--2.417      0.770           0.600          0.196--1.838    0.371
                                                  SBB                    18                          3          8.45            0.821          0.252--2.680      0.744           0.404          0.116--1.410    0.155
  CCI ≥3 (n=516)                                                                                                                                                                                                
                                      No BB use   363                    171                         5.78       1 (reference)                                    1 (reference)                                  
                                      BB use      153                    64                          5.78       0.810           0.608--1.080   0.151             0.690           0.502--0.949   0.023           
                                                  NSBB                   115                         43         5.75            0.703          0.504--0.983      0.039           0.633          0.438--0.913    0.014
                                                  SBB                    78                          33         6.71            0.793          0.546--1.151      0.223           0.642          0.424--0.971    0.036
  No hypertension (n=573)                                                                                                                                                                                       
                                      No BB use   506                    128                         6.07       1 (reference)                                    1 (reference)                                  
                                      BB use      67                     14                          7.39       0.730           0.420--1.268   0.264             0.604           0.341--1.071   0.084           
                                                  NSBB                   59                          12         7.17            0.710          0.393--1.283      0.257           0.578          0.312--1.069    0.080
                                                  SBB                    18                          4          9.02            0.738          0.272--1.997      0.549           0.615          0.218--1.733    0.358
  Hypertension (n=293)                                                                                                                                                                                          
                                      No BB use   154                    82                          4.92       1 (reference)                                    1 (reference)                                  
                                      BB use      139                    57                          5.87       0.642           0.458--0.901   0.010             0.647           0.452--0.926   0.017           
                                                  NSBB                   92                          36         5.55            0.617          0.417--0.913      0.016           0.632          0.414--0.964    0.033
                                                  SBB                    87                          32         6.89            0.534          0.354--0.804      0.003           0.564          0.365--0.873    0.010
  No cardiovascular disease (n=527)                                                                                                                                                                             
                                      No BB use   470                    113                         6.07       1 (reference)                                    1 (reference)                                  
                                      BB use      57                     13                          7.28       0.844           0.475--1.500   0.564             0.638           0.351--1.159   0.140           
                                                  NSBB                   51                          12         7.17            0.881          0.486--1.598      0.678           0.640          0.344--1.190    0.159
                                                  SBB                    16                          3          9.17            0.630          0.200--1.985      0.430           0.484          0.143--1.644    0.245
  Cardiovascular disease (n=339)                                                                                                                                                                                
                                      No BB use   190                    97                          5.47       1 (reference)                                    1 (reference)                                  
                                      BB use      149                    58                          6.10       0.653           0.472--0.904   0.010             0.655           0.463--0.927   0.017           
                                                  NSBB                   100                         36         5.88            0.601          0.410--0.881      0.009           0.613          0.406--0.926    0.020
                                                  SBB                    89                          33         6.99            0.590          0.397--0.876      0.009           0.597          0.390--0.913    0.017

CCI score: 1, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, gastric ulcer, mild liver disease, and diabetes mellitus without complication; 2, diabetes mellitus with retinopathy, neuropathy, and nephropathy, hemiparesis, kidney disease (≥ moderate), and non-metastatic solid tumor, leukemia, lymphoma, and multiple myeoloma; 3, liver disease (≥ moderate); 6, metastatic solid tumor, and acquired immunodeficiency syndrome.

BB, beta blocker; CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio; NSBB, non-selective beta blocker; SBB, selective beta blocker.

^\*^Adjusted for age (20--39, 40--59, 60--79, ≥80 years), year of diagnosis, prior use of diuretics (yes/no), aspirin (yes/no), and statins (yes/no).

![OS and DSS of patients with ovarian cancer based on BB use (NSBB or SBB) and no BB use in (A) CCI ≥3, (B) hypertension, and (C) cardiovascular disease.\
BB, beta blocker; CCI, Charlson Comorbidity Index; DSS, disease-specific survival; NSBB, non-selective beta blocker; OS, overall survival; SBB, selective beta blocker.](jgo-29-e82-g004){#F4}

Impact of hypertension
----------------------

BB medication was associated with better survival outcome in ovarian cancer patients with hypertension (adjusted HR=0.647; 95% CI=0.452--0.926; p=0.017). Both NSBB (adjusted HR=0.632; 95% CI=0.414--0.964; p=0.033) and SBB (adjusted HR=0.564; 95% CI=0.365--0.873; p=0.010) were associated with better survival outcome in patients with hypertension ([Table 3](#T3){ref-type="table"} and [Fig. 4B](#F4){ref-type="fig"}).

Impact of cardiovascular disease
--------------------------------

Patients with ovarian cancer were considered as also having cardiovascular disease when they had more than one condition among hypertension, myocardial infarction, angina pectoris, and congestive heart failure. BB medication was associated with better survival outcome in ovarian cancer patients with cardiovascular disease (adjusted HR=0.655; 95% CI=0.463--0.927; p=0.017). Both NSBB (adjusted HR=0.613; 95% CI=0.406--0.926; p=0.020) and SBB (adjusted HR=0.597; 95% CI=0.390--0.913; p=0.017) were associated with better survival outcome in patients with cardiovascular disease ([Table 3](#T3){ref-type="table"} and [Fig. 4C](#F4){ref-type="fig"}).

Multivariate Cox proportional hazards model and disease-specific survival (DSS)
-------------------------------------------------------------------------------

Kaplan Meier survival curve was generated according to DSS. NSBB was associated with better DSS outcome in ovarian cancer patients with CCI ≥3 (p=0.011, [Fig. 4A](#F4){ref-type="fig"}). Although not statistically significant, BB use was associated with a tendency of better DSS outcome which is in accordance to the results with overall survival (OS) ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}).

Multivariate Cox proportional hazards analysis was performed according to both OS and DSS to identify an independent prognostic factor in ovarian cancer patients regardless of BB related underlying diseases. Age ≥60 and CCI ≥3 were independent prognostic factors for both lower OS and DSS. Hypertension and cardiovascular disease were not independent prognostic factors for both OS and DSS. Longer duration of both NSBB and SBB medication (≥1 year) was an independent favorable prognostic factor for OS in ovarian cancer patients (HR=0.266; 95% CI=0.163--0.435; p\<0.001), while only NSBB medication (≥1 year) was an independent favorable prognostic factor for DSS (HR=0.178; 95% CI=0.043--0.746; p=0.018, [Table 4](#T4){ref-type="table"}).

###### Multivariate Cox proportional hazards model in ovarian cancer patients using BBs
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  Variables          BB use                   NSBB use   SBB use                                                                                                          
  ------------------ ------------------------ ---------- -------------- --------------- --------- -------------- --------------- --------- -------------- --------------- ---------
  OS (281 events)                                                                                                                                                         
                     Duration of medication                                                                                                                               
                                              No         1                                        1                                        1                              
                                              \<1 year   0.873          0.635--1.201    0.405     0.666          0.464--0.956    0.028     0.677          0.441--1.041    0.076
                                              ≥1 year    0.266          0.163--0.435    \<0.001   0.289          0.150--0.558    \<0.001   0.253          0.127--0.504    \<0.001
                     Age (≥60 years)          2.470      1.857--3.286   \<0.001         2.632     1.961--3.532   \<0.001         2.526     1.867--3.416   \<0.001         
                     CCI                                                                                                                                                  
                                              0          1                                        1                                        1                              
                                              1--2       3.416          1.445--8.077    0.005     2.986          1.257--7.093    0.013     3.682          1.443--9.393    0.006
                                              ≥3         8.631          3.798--19.616   \<0.001   7.265          3.178--16.608   \<0.001   9.476          3.861--23.260   \<0.001
                     Hypertension             1.389      0.812--2.378   0.230           1.349     0.774--2.349   0.291           1.218     0.707--2.099   0.477           
                     Cardiovascular disease   0.842      0.497--1.428   0.524           0.806     0.467--1.388   0.436           0.931     0.546--1.587   0.793           
                     Prior use of diuretics   2.560      1.955--3.353   \<0.001         2.606     1.976--3.437   \<0.001         2.506     1.890--3.321   \<0.001         
                     Prior use of statins     0.370      0.269--0.509   \<0.001         0.367     0.261--0.516   \<0.001         0.312     0.216--0.451   \<0.001         
  DSS (100 events)                                                                                                                                                        
                     Duration of medication                                                                                                                               
                                              No         1                                        1                                        1                              
                                              \<1 year   0.766          0.430--1.363    0.364     0.590          0.306--1.140    0.116     0.619          0.284--1.351    0.228
                                              ≥1 year    0.258          0.108--0.619    0.002     0.178          0.043--0.746    0.018     0.361          0.125--1.042    0.060
                     Age (≥60 years)          1.893      1.170--3.063   0.009           1.999     1.216--3.288   0.006           1.772     1.070--2.936   0.026           
                     CCI                                                                                                                                                  
                                              0          1                                        1                                        1                              
                                              1--2       2.734          0.930--8.035    0.067     2.476          0.837--7.321    0.101     3.246          0.952--11.063   0.060
                                              ≥3         5.202          1.869--14.477   0.002     4.610          1.642--12.940   0.004     6.704          2.077--21.641   0.001
                     Hypertension             2.149      0.648--7.127   0.211           1.892     0.566--6.326   0.300           1.953     0.582--6.548   0.278           
                     Cardiovascular disease   0.383      0.119--1.236   0.108           0.386     0.119--1.245   0.111           0.412     0.127--1.334   0.139           
                     Prior use of diuretics   4.149      2.626--6.555   \<0.001         4.072     2.563--6.471   \<0.001         4.226     2.630--6.790   \<0.001         
                     Prior use of statins     0.321      0.182--0.566   \<0.001         0.324     0.176--0.595   \<0.001         0.291     0.155--0.545   \<0.001         

BB, beta blocker; CCI, Charlson Comorbidity Index; CI, confidence interval; DSS, disease-specific survival; HR, hazard ratio; NSBB, non-selective beta blocker; OS, overall survival; SBB, selective beta blocker.

DISCUSSION
==========

Immune-suppression by both physical and psychological stress is a contributory cause of tumorigenesis and disease progression \[[@B24]\]. Previous epidemiologic studies have shown that prolonged exposure of beta adrenergic receptors on ovarian cancer cell surfaces to catecholamines due to chronic stress causes further tumor growth \[[@B25]\]. There have been several retrospective and small pilot clinical studies and preclinical studies investigating the potential role of BBs, but the results were inconsistent.

First, small cohorts in single retrospective center studies with different approaches, patient characteristics, and confounders between the series may have been obstacles to elucidation of the clinical impact of BBs in ovarian cancer \[[@B15][@B16][@B20]\]. Second, most previous studies did not further analyze the effect of NSBBs and SBBs in ovarian cancer \[[@B15][@B16][@B18]\]. Further, there was no specific mention of "duration" or a clear "definition" of BB medication use in the majority of the previous series \[[@B15][@B16][@B17][@B20]\]. Tumorigenesis and disease progression in ovarian cancer due to stress responses is considered a "chronic process" and the duration of use among long-term BB users is important to verify efficacy. We additionally analyzed the effect of NSBBs and SBBs. Further, we strictly defined BB users on the basis of at least one prescription within 90 days of diagnosis.

Finally, there has been no analysis to find a sub-group of patients who could more benefit from BB use. Johannesdottir et al. \[[@B18]\] found no promising effect of BB use on OS in ovarian cancer in their population-based cohort study by using the Danish cancer registry. However, BB use showed a tendency of association with improved survival outcomes in ovarian cancer when administered in an elderly group in the above study in accordance with the results in our series, although they found no statistical significance. A relatively short period of median BB use of 19 months and no subgroup analysis of BBs was a major shortcoming of the above series, preventing conclusions about the association of long term BB use with better prognosis. Above all, 2.55 years is a relatively short follow-up period to truly understand the long-term survival effect of BB medication in ovarian cancer. In our study, the effect of BB was analyzed with 6.71 years of long-term follow up in BB users and 5.98 years in non-users. In addition, duration of medication use was categorized into several groups for better analysis. Also, multivariate analysis according to DSS in addition to OS was performed to truly know the effect of BB.

In our study, BB use in elderly patients (≥60 years) and over a long term (≥1 year) showed prognostic improvement in ovarian cancer. Further, BB medication use was associated with better survival outcomes in ovarian cancer patients with cardiovascular and/or other underlying disease (CCI ≥3). Prolonged exposure to catecholamine due to chronic stress has been correlated with tumorigenesis and disease progression in epidemiologic research \[[@B25]\]. Elderly patients also tend to have a higher incidence of chronic cardiovascular disease, which may lead to longer intake of BBs compared to younger groups. Further, these patients are more prone to stress and may have been exposed for a longer period. Social isolation is an additional problem among the elderly and network support to enable them to deal with stress better by decreasing depression and eventually lowering circulating and disease-related norepinephrine levels should be considered \[[@B10]\]. BBs show their anticancer effects biologically or immunologically and by reducing disease-associated chronic stress psychologically \[[@B17]\]. We consider exposure to BBs for a long period of time due to higher incidence of chronic medical conditions and multiple psycho-social effects to be of paramount importance in their anticancer effects. BBs can be beneficial agents for improving oncologic outcomes in patients with ovarian cancer, particularly in the elderly (≥60 years), considering the above background.

NSBB use (≥180 days) was associated with improved OS with a relatively shorter medication period than SBB use (≥720 days) in our series. Further, only NSBB medication (≥1 year) was an independent favorable prognostic factor for DSS in multivariate analysis. The reason for NSBBs showing an improved anticancer effect in comparison to SBBs has not been elucidated. We speculate that this may be because NSBBs cover a broad spectrum of beta adrenergic receptors compared to SBBs. NSBBs show anticancer effects by blocking the adrenergic receptor b2 (ADRB2) pathway which activates PKA and increases VEGF and MMP expression \[[@B13]\].

Retrospective study design was a limitation of the present study. BB was used because of its related underlying disease, and bias may still remain even confounders were meticulously adjusted by various methods. Further, detailed subtypes of ovarian cancer could not be identified from the current database. However, high general applicability and low selection bias compared to previous series was a strength of this study. Social characteristics which can be potential confounders were systematically adjusted based on the CCI system. Furthermore, confirmatory analysis was performed by generating multivariate Cox proportional hazards model by adopting both OS and DSS to minimize above mentioned problem.

After all, a prospective clinical trial may be the definite way to know whether BB truly has an anticancer effect on ovarian cancer without any potential bias. The only prospective randomized trial of BB use in ovarian cancer treatment was recently reported by Jang et al. \[[@B26]\], and propranolol (NSBB) was associated with significant decrease in postoperative cancer antigen levels (CA-125), but not with disease-free survival. A small number of patients (n=22) from a single institution with a short follow-up duration (median, 17 months) was a major shortcoming of this series. Above all, there was no analysis of important parameters such as overall response rate, severe adverse events, and quality of life of the patients, making it difficult to draw conclusions. At the same time, Al-Niaimi et al. \[[@B21]\] reported improved survival outcomes due to perioperative metoprolol (SBB) intake with "Minnesota protocol" among a subgroup of patients who were considered "at risk". SBBs were tested in patients with no cardiovascular disease including hypertension, potentially repositioning BBs as a new targeted agent in ovarian cancer treatment. Currently, a pilot and prospective study on feasibility of propranolol (NSBB) use in ovarian cancer treatment is ongoing ([NCT01308944]{.ul}, [NCT01504126]{.ul}, and [NCT02013492]{.ul}). Results of these studies will provide a better picture of the anticancer effects of BBs and will be a basis for further well-designed multicenter clinical trials.

In conclusion, BB use was associated with better survival outcomes in ovarian cancer in cases of long-term use, in presence of hypertension, in cardiovascular and/or other underlying disease (CCI ≥3), and in older patients. If BBs are found to show survival improvement in ovarian cancer, they may be re-positioned as new targeted agents, relieving the economic burden involved in cancer treatment for both government and patients by substituting conventional targeted agents.
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